DOP2001000164A - METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN - Google Patents

METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN

Info

Publication number
DOP2001000164A
DOP2001000164A DO2001000164A DO2001000164A DOP2001000164A DO P2001000164 A DOP2001000164 A DO P2001000164A DO 2001000164 A DO2001000164 A DO 2001000164A DO 2001000164 A DO2001000164 A DO 2001000164A DO P2001000164 A DOP2001000164 A DO P2001000164A
Authority
DO
Dominican Republic
Prior art keywords
ryk
diseases
angiogenesis
ryk protein
protein
Prior art date
Application number
DO2001000164A
Other languages
Spanish (es)
Inventor
Alya Zolotorev
Steve Roczniak
Nathalie A Dubois-Stringfellow
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of DOP2001000164A publication Critical patent/DOP2001000164A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se encontró que La proteína Ryk tenía una novedosa actividad en la regulación de la angiogénesis. Se construyeron nuevas proteínas Ryk variantes Que son ventajosas para modular la actividad formadora de capilares de las células endoteliales. Las proteínas Ryk variantes pueden ser utilizadas como agentes terapéuticos en enfermedades tales como el cáncer, la cicatrización de heridas, las retinopatías diabéticas, la degeneración macular y las enfermedades cardiovasculares, así como otras enfermedades o trastornos clínicos en la que la Angiogénesis está involucrada en la causa o el tratamiento de la enfermedad.It was found that Ryk protein had a novel activity in the regulation of angiogenesis. New Ryk protein variants were constructed which are advantageous for modulating capillary-forming activity of endothelial cells. Variant Ryk proteins can be used as therapeutic agents in diseases such as cancer, wound healing, diabetic retinopathies, macular degeneration and cardiovascular diseases, as well as other diseases or clinical disorders in which Angiogenesis is involved in cause or treatment of the disease.

DO2001000164A 2000-05-10 2001-05-10 METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN DOP2001000164A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56878300A 2000-05-10 2000-05-10

Publications (1)

Publication Number Publication Date
DOP2001000164A true DOP2001000164A (en) 2002-05-15

Family

ID=24272718

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2001000164A DOP2001000164A (en) 2000-05-10 2001-05-10 METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN

Country Status (13)

Country Link
EP (1) EP1287121A2 (en)
JP (1) JP2004527206A (en)
AR (1) AR028424A1 (en)
AU (1) AU2001261343A1 (en)
CA (1) CA2408349A1 (en)
CO (1) CO5300464A1 (en)
DO (1) DOP2001000164A (en)
EC (1) ECSP014068A (en)
GT (1) GT200100079A (en)
PE (1) PE20011218A1 (en)
SV (1) SV2002000442A (en)
UY (1) UY26696A1 (en)
WO (1) WO2001085789A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066087A2 (en) * 2002-02-06 2003-08-14 Developgen Aktiengesellschaft Für Entwicklungsbiologische Forschung Kinases involved in the regulation of energy homeostasis
JO3283B1 (en) 2011-04-26 2018-09-16 Sanofi Sa Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
EA035674B1 (en) 2014-07-18 2020-07-24 Санофи Method of determining whether a patient suspected to suffer from cancer is a candidate for aflibercept therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023429A1 (en) * 1992-05-11 1993-11-25 Ludwig Institute For Cancer Research Receptor-type tyrosine kinase-like molecules
WO1996020403A1 (en) * 1994-12-23 1996-07-04 Ludwig Institute For Cancer Research Assay, receptor proteins and ligands
AU4278299A (en) * 1998-06-11 1999-12-30 Astrazeneca Ab Human receptor tyrosine kinase
ES2316194T3 (en) * 1998-10-28 2009-04-01 Cornell Research Foundation, Inc. METHODS FOR THE REGULATION OF ANGIOGENESIS AND VASCULAR INTEGRITY USING THE BDNF, NT-3 AND NT-4 LIGANDS.

Also Published As

Publication number Publication date
ECSP014068A (en) 2002-02-25
WO2001085789A2 (en) 2001-11-15
AU2001261343A1 (en) 2001-11-20
UY26696A1 (en) 2001-12-28
JP2004527206A (en) 2004-09-09
WO2001085789A3 (en) 2002-05-16
SV2002000442A (en) 2002-07-03
GT200100079A (en) 2001-12-31
AR028424A1 (en) 2003-05-07
CA2408349A1 (en) 2001-11-15
PE20011218A1 (en) 2002-02-01
CO5300464A1 (en) 2003-07-31
EP1287121A2 (en) 2003-03-05

Similar Documents

Publication Publication Date Title
UY28396A1 (en) VEGF TRUMPS AND THERAPEUTIC USES OF THE SAME
CY1121447T1 (en) COMPOSITIONS FOR INCREASING TELEVISION ACTIVITY
ATE290401T1 (en) TOPICAL AGENTS FOR NAIL FUNGUS DISEASES
DK1641483T3 (en) Fusion Proteins
IL117645A (en) Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
TR200101307T2 (en) Antranilic acid amides and their use as drugs.
ES2157422T3 (en) TRIGLICERIDS AND ETHYL ESTERS OF PHENYLALCANOIC ACID AND PHENYLALKYEN ACID USEFUL IN THE TREATMENT OF DIFFERENT DISORDERS.
DE602005020178D1 (en) 5,6,7-TRIHYDROXYPHEPTANIC ACIDS AND ANALOGS FOR THE TREATMENT OF EYE DISEASES AND DISEASES ASSOCIATED WITH HYPERPROLIFERATIVES AND ANGIOGENIC REACTIONS
DOP2001000164A (en) METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN
ATE330596T1 (en) USE OF 3-BEZOYLPHENYLACETIC ACID DERIVATIVES FOR THE TREATMENT OF RETINAL DISEASES
DE60107444D1 (en) USE OF A POLLEN EXTRACT CONTAINER FOR THE TREATMENT OF EDEMS
ES2110057T3 (en) MEDICINAL COMPOSITION CONTAINING TCF-II.
ATE555787T1 (en) TREATMENT EFFECTS OF EXCESS REACTIVE OXYGEN SPECIES
AR027764A1 (en) PROTEINS THAT HAVE ACTIVITY AS AN ANGIOGENESIS MODULATOR
DK1596879T3 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
SV2002000362A (en) PROTEINS THAT HAVE AN ANGIOGENESIS MODULATING ACTIVITY REF.MSB-7265-SV
ATE374048T1 (en) USE OF MATRIX PROTEIN FOR CONTROLLED TISSUE REGENERATIONS
TR199901385T2 (en) Piperidin t�revleri.
AR011907A1 (en) USE OF 4- (2,2-DIMETHYLPROPANOL) BUTANOIC ACID (PIVAGABIN) TO PREPARE A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FORMS OF DEPRESSIVE ANXIETY.
WO2001074852A3 (en) Protein having activity as an angiogenesis modulator
ATE337790T1 (en) USE OF CORTISOL SEQUESTRING AGENTS TO TREAT HYPERCORTISOLAEMIA-RELATED DISEASES
SV1994000023A (en) SUBSTITUTED PYRROLES REF. RAN 4070/90
DE60234786D1 (en) PEPTIDE BAITS FOR THE MANUFACTURE OF MEDICAMENTS FOR THE PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASES OR PROBLEMS CONNECTED WITH THE OUTCOME OF ANTIBODIES TARGETED AGAINST EXOGENE PROTEINS ARE DETERMINED
TR200000916T2 (en) Substituted piperidine derivatives.
ATE224730T1 (en) AGENTS FOR THE TREATMENT OF PIGMENTATION DISORDERS